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Abstract
Background: In experimental models of fetal alcohol spectrum disorder (FASD), cerebellar hypoplasia and
hypofoliation are associated with insulin and insulin-like growth factor (IGF) resistance with impaired signaling
through pathways that mediate growth, survival, plasticity, metabolism, and neurotransmitter function. To more
directly assess the roles of impaired insulin and IGF signaling during brain development, we administered
intracerebroventricular (ICV) injections of si-RNA targeting the insulin receptor, (InR), IGF-1 receptor (IGF-1R), or
IGF-2R into postnatal day 2 (P2) Long Evans rat pups and examined the sustained effects on cerebellar function,
structure, and neurotransmitter-related gene expression (P20).
Results: Rotarod tests on P20 demonstrated significant impairments in motor function, and histological studies
revealed pronounced cerebellar hypotrophy, hypoplasia, and hypofoliation in si-InR, si-IGF-1R, and si-IGF-2R treated
rats. Quantitative RT-PCR analysis showed that si-InR, and to a lesser extent si-IGF-2R, broadly inhibited expression
of insulin and IGF-2 polypeptides, and insulin, IGF-1, and IGF-2 receptors in the brain. ELISA studies showed that
si-InR increased cerebellar levels of tau, phospho-tau and b-actin, and inhibited GAPDH. In addition, si-InR, si-IGF-1R,
and si-IGF-2R inhibited expression of choline acetyltransferase, which mediates motor function. Although the ICV
si-RNA treatments generally spared the neurotrophin and neurotrophin receptor expression, si-InR and si-IGF-1R
inhibited NT3, while si-IGF-1R suppressed BDNF.
Conclusions: early postnatal inhibition of brain InR expression, and to lesser extents, IGF-R, causes structural and
functional abnormalities that resemble effects of FASD. The findings suggest that major abnormalities in brains
with FASD are mediated by impairments in insulin/IGF signaling. Potential therapeutic strategies to reduce the
long-term impact of prenatal alcohol exposure may include treatment with agents that restore brain insulin and
IGF responsiveness.
Background
In the central nervous system (CNS), insulin and insu-
lin-like growth factors (IGFs) transmit pro-growth and
pro-survival signals by activating complex intracellular
pathways, beginning with ligand binding to cell surface
receptors. Activated receptor tyrosine kinases phosphor-
ylate insulin receptor substrate (IRS) proteins [1], which
then interact with src homology domain-containing
adaptor molecules to promote mitogenesis, cell survival,
gene expression, metabolism, and motility [1-3]. Insulin,
IGF-1 and IGF-2, and their corresponding receptors are
abundantly expressed in neurons [1,4,5] and glia [6-8]
throughout the brain, but the highest levels are distribu-
ted in the hypothalamus, temporal lobe, and cerebellum
[1], i.e. major targets of ethanol-mediated neurotoxicity.
Given that insulin and IGF mediate neuronal survival,
plasticity, energy metabolism, and neurotransmitter
function [1,9-12], we hypothesized that sustained
impairments in these signaling pathways would have
dire consequences with respect to CNS function.
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alcohol-mediated toxicity and teratogenesis. The con-
stellation of neurodevelopmental and behavioral
abnormalities caused by chronic gestational exposure to
alcohol is termed, “fetal alcohol spectrum disorder”
(FASD) [13-19]. In the cerebellum, effects of FASD
include hypoplasia, hypo-foliation, reduced neuronal
survival, disordered cell migration, and impaired motor
function [15-17,20-22]. There is now sufficient evidence
that many of these adverse effects of ethanol are
mediated by impairments in insulin and IGF signaling
[22-27]. Ethanol impairs insulin and IGF signaling
in immature neuronal cells [28] by reducing ligand-
receptor binding, and inhibiting receptor tyrosine kinase
activation of downstream pathways through IRS [22-27].
Consequences include, down-regulation of insulin/IGF
responsive genes [22,24,26,29,30], increased oxidative
stress, DNA damage, lipid peroxidation, and mitochon-
drial dysfunction [24,25,31,32], and reduced neuronal
survival, plasticity [24,32,33], energy metabolism, and
choline acetyltransferase (ChAT) activity [22,25,27,34].
ChAT is a major neurotransmitter that is needed for
cognitive and motor functions [35-38].
The present study examines the degree to which
inhibition of insulin/IGF signaling through their corre-
sponding receptors is sufficient to mimic ethanol-
impaired cerebellar development and function. We
utilized an in vivo model in which insulin or IGF recep-
tor genes were inhibited in rat pup brains by intracereb-
roventricular (ICV) delivery of si-RNA duplexes
targeting the insulin receptor (si-InR), IGF-1 receptor
(si-IGF-1R), or IGF-2 receptor (si-IGF-2R), or nonspeci-
fic sequences (si-Scr) [39,40], and examined the sus-
tained effects of these si-RNA treatments on motor
function, cerebellar structure, and neurotransmitter and
neurotrophin gene expression. The cerebellum was the
focus of our investigations because: 1) it develops mainly
in the early postnatal period; 2) it is one of the primary
targets of ethanol-mediated neurotoxicity (other sites
include the hippocampus, corpus callosum, cerebral cor-
tex, and caudate nucleus); and 3) it expresses abundant
levels of insulin and IGF receptors during development
[1,20,22,27,41-43].
Methods
Materials
Qiazol reagent, EZ1 RNA universal tissue kit, Quanti-
Tect SYBR Green polymerase chain reaction (PCR) mas-
ter mix, and the BIO Robot Z1 were from Qiagen Inc
(Valencia, CA). Monoclonal antibodies to b-Actin, tau,
phospho-tau (AT8-S199, S202, T205), brain-derived
neurotrophic factor (BDNF), nerve growth factor (NGF),
neurotrophin 3 (NT3), neurotrophin 4 (NT4), glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH), choline
acetyltransferase (ChAT), acetylcholinesterase (AChE),
and 4-hydroxy-2-nonenal (HNE) were purchased from
Abcam Inc. (Cambridge, MA), Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA), or Chemicon International
(Tecumsula, CA). The 85G6 aspartyl-(asparaginyl)-b-
hydroxylase (AAH) monoclonal antibody was generated
to human recombinant protein and purified over Protein
G columns (Healthcare, Piscataway, NJ) [44]. Small
interfering RNA duplex molecules and Dharmafect
reagent were purchased from Dharmacon, Inc. (Chicago,
IL). Histofix was purchased from Histochoice (Amresco,
Solon, OH). The AMV first strand cDNA synthesis kit
was obtained from Roche Diagnostics Corporation
(Indianapolis, IN). Diaminobenzidine (DAB) chromogen
was from Vector Laboratories (Burlingame, CA). PCR
primers were purchased from Sigma Chemical Co. (St.
Louis, MO). Enzyme-linked immunosorbant assay
(ELISA) 96-well plates and the ELISA plate washer were
from Nunc (Rochester, NY). Horseradish peroxidase
(HRP)-conjugated secondary antibody and Amplex Red
soluble fluorophore were from Invitrogen (Carlsbad,
CA). HRP-labeled polymer conjugated secondary anti-
body used for immunohistochemistry was purchased
from Dako Corp (Carpinteria, CA). The SpectraMax M5
microplate reader was purchased from Molecular
Devices Corp. (Sunnyvale, CA). NanoOrange and the
bicinchoninic acid (BCA) assay reagents were from
Pierce chemical Corp. (Rockford, IL). All other fine che-
micals were purchased from CalBiochem (Carlsbad,
CA), Pierce (Rockford, IL), or Sigma (St. Louis, MO).
Gene Delivery Model
Postnatal day 2 (P2) Long Evans rat pups were given a
single intracerebroventricular (ICV) injection of small
interfering RNA duplexes (si-RNA) targeting the insulin
receptor (si-InR) [INSR NM_017071], IGF-1 receptor
(si-IGF-1R) [IGF1R NM_052807], IGF-2R (si-IGF-2R)
[IGF2R NM_012756], or nonspecific sequences
(Scrambled; si-Scr) [NM D-001210-01-20]. For each rat,
0.4 nmol si-RNA plus 100 ng recombinant green fluor-
escent protein (GFP) expressing plasmid were com-
plexed with 10 μl of Dharmafect reagent, and injected
into the right frontal region over the lateral ventricle
using a Hamilton syringe with a 26-gauge needle as pre-
viously described [39,40]. GFP expression, which was
under the control of a CMV promoter [45], was used to
monitor success of transfection. This was accomplished
by sacrificing rats (N = 4 per group) at regular intervals
after the ICV gene delivery, and measuring GFP mRNA
levels in whole brain homogenates by qRT-PCR analysis.
Those studies demonstrated peak levels of GFP expres-
sion within 2-3 days after ICV gene delivery, followed
by a gradual decline in GFP expression. Importantly,
GFP expression persisted over the time course of the
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[39]. All rats survived the procedure, and none exhibited
adverse responses such as, failure to thrive, poor groom-
ing, reduced physical activity, or weight loss.
Gene expression and histological studies pertaining to
the effects of si-InR, si-IGF-1R, or si-IGF-2R were per-
formed with cerebella harvested on P24. Upon sacrifice,
freshly harvested cerebella were divided in the mid-
sagittal plane. One hemisphere was immersion fixed in
Histofix, and the other was snap-frozen in a dry ice/
methanol bath and stored at -80°C for mRNA and
protein studies. The fixed tissue was embedded in
paraffin and used to generate hematoxylin and eosin
(H&E) stained histological sections (5 μm-thick). In
addition, adjacent sections were immunostained with
monoclonal antibodies to 4-hydroxy-2-nonenal (HNE)
or aspartyl-(asparaginyl)-b-hydroxylase (AAH), as pre-
viously described [44], except that immunoreactivity was
detected with HRP-labeled polymer-conjugated second-
a r ya n t i b o d ya n dD A B .T h es ections were lightly coun-
terstained with Hematoxylin and examined by light
microscopy. Our protocol was approved by the Institu-
tional Animal Care and Use Committee at Lifespan-
Rhode Island Hospital, and it conforms to the guidelines
set by the National Institutes of Health.
Rotarod Testing
We used rotarod testing to assess long-term effects of
ICV si-InR, si-IGF-1R and si-IGF-2R treatments on
motor function [46,47]. On P19, rats were trained to
remain balanced on the rotating Rotamex-5 apparatus
(Columbus Instruments) at 1-5 rpm. On P20, rats (N =
8-10 per group) were administered 10 trials at incre-
mental speeds up to 10 rpm, with 10 minutes rest
between each trial. The latency to fall was automatically
detected and recorded with photocells placed over the
rod. However, trials were stopped after 30 seconds to
avoid exercise fatigue. Data from trials 1-3 (2-5 rpm),
4-7 (5-7 rpm), and 8-10 (8-10 rpm) were culled and
analyzed using the Mann-Whitney test.
Quantitative Reverse Transcriptase Polymerase Chain
Reaction (qRT-PCR) Analysis
We used qRT-PCR to measure mRNA expression as
previously described [48-50]. In brief, cerebella were
homogenized in Qiazol reagent, and total RNA was iso-
lated using the EZ1 RNA universal tissue kit and the
BIO Robot EZ1. RNA was reverse transcribed using ran-
dom oligodeoxynucleotide primers and the AMV First
Strand cDNA synthesis kit. The resulting cDNA tem-
plates were used in qPCR amplification reactions with
gene specific primer pairs (Additional File 1) [51]. Pri-
mers were designed using MacVector 10 software (Mac-
Vector, Inc., Cary, NC) and their target specificities was
verified using NCBI-BLAST (Basic Local Alignment
Search Tool). The amplified signals were detected and
analyzed using the Mastercycler ep realplex instrument
and software (Eppendorf AG, Hamburg, Germany).
Relative mRNA abundance was calculated from the ng
ratios of specific mRNA to 18S rRNA measured in the
same samples. Assays were performed in triplicate.
Inter-group statistical comparisons were made using the
calculated mRNA/18S ratios.
Enzyme Linked Immunosorbent Assay (ELISA)
Cerebellar homogenates were prepared in radioimmuno-
precipitation assay (RIPA) buffer containing protease
and phosphatase inhibitors [50]. Protein concentrations
were determined using the bicinchoninic (BCA) assay.
We performed direct binding ELISAs to measure immu-
noreactivity. Samples containing 50 ng protein diluted
in Tris buffered saline, pH 7.4 (TBS) were adsorbed to
the bottom flat surfaces of 96-well polystyrene ELISA
plates overnight at 4°C [44]. Non-specific binding sites
were blocked by a 3-hour room temperature incubation
with 300 μl/well of TBS + 0.05% Tween 20 + 3% BSA.
Samples were then incubated with 0.1-0.5 μg/ml pri-
mary antibody for 1 h at 37°C. Immunoreactivity was
detected with horseradish peroxidase (HRP)-conjugated
secondary antibody and Amplex Red soluble fluoro-
phore [44]. Fluorescence was measured (Ex 530/Em
590) in a SpectraMax M5 microplate reader. Parallel
negative control assays had primary, secondary, or both
antibodies omitted. Between steps, reactions were rinsed
3 times with TBS + 0.05% Tween 20 using a Nunc
ELISA plate washer. Levels of immunoreactivity were
normalized to protein content in the wells, which was
measured using NanoOrange reagent.
Statistical Analysis
Data corresponding to levels of gene expression or
immunoreactivity are depicted in boxplot graphs repre-
senting the means (horizontal bars), 95% confidence
intervals (box limits), and range (whiskers) for each
group. Inter-group comparisons were made using the
Kruskal-Wallis one-way Analysis of variance (ANOVA)
with the Dunn’s multiple comparisons post-hoc test of
statistical significance. Statistical analyses were per-
formed using the GraphPad Prism 5 software (San
Diego, CA) and significant P-values (<0.05) are indicated
within the graph panels.
Results
ICV injection of si-RNA targeting the insulin or IGF
receptors impairs motor performance
Rotarod tests are used to assess sensorimotor coordina-
tion and they provide a highly sensitive index of damage
to the cerebellum [46,52]. Rotarod test results were
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and 7-10, in which the rotation speeds were incremen-
t e df r o m2t o4 . 5 ,5t o7 . 5 ,a n d8t o1 0r p m ,r e s p e c -
tively. The mean ± S.E.M. latency to fall periods were
calculated and results are depicted graphically. In the
two lower speed trial sets, all 4 groups performed simi-
larly (Figures 1A-1B), whereas in the final and most
challenging trial series, rotarod performance was signifi-
cantly impaired in the si-InR, si-IGF-1R, and si-IGF-2R
relative to si-Scr treated controls (Figure 1C).
Cerebellar hypofoliation and hypotrophy following ICV
injection of si-InR, si-IGF-1R, or si-IGF-2R
C e r e b e l l aw e r eh a r v e s t e dt oexamine histopathological
effects of the ICV siRNA treatments, on P9 and P16
(Figure 2). Cerebella from si-Scr transfected controls
had well-developed complex foliation with regular pat-
terns of major deep and minor shallow grooving, slender
white matter cores, compact and densely populated
granule and Purkinje cell layers, and a uniform molecu-
lar layer (Figures 2A, 2E, 2I). In contrast, P9 brains,
including cerebella from si-InR, si-IGF-1R, or si-IGF-2R-
transfected rats were smaller, and they had relatively
simplified, shallow, blunted, and irregular folia, irregu-
larly thickened white matter cores, and conspicuously
hypocellular cortical granule cell layers relative to con-
trol (Figures 2B-2D, 2F-2H). The si-IGF-2R transfected
rats had the most pronounced simplification and hypo-
trophy of cerebellar folia compared with all other groups
(Figure 2). It is noteworthy that the Purkinje layer of
cortex was consistently preserved, whereas the granule
cell and molecular layers were variably affected by the
si-RNA treatments. The relative sparing of Purkinje cells
was most likely due to the fact that they develop in
utero, while the granule and molecular layers develop
mainly within the early postnatal period [42,43,53] dur-
ing which the ICV si-RNAs were delivered. At the later
time point (P16), the effects of the siRNA treatments on
cerebellar structure were subtler, but still manifested by
relatively simplified and shallow foliation relative to con-
trol (Figures 2I-2L).
Adjacent histological sections were immunostained
with monoclonal antibodies to HNE to assess levels of
oxidative stress and lipid peroxidation, or AAH, which
is a downstream target of insulin/IGF signaling and reg-
ulator of neuronal migration [44,45] (Additional File 2).
Previous studies demonstrated that chronic in utero
ethanol exposure increases HNE and reduces AAH
immunoreactivity [22,44,54]. In the present study, si-Scr
treated control cerebella had low levels of HNE
Figure 1 Effects of si-InR, si-IGF-1R, and si-IGF-2R ICV injections
on motor performance. P2 Long Evans rat pups were
administered intracerebroventricular (ICV) injections of si-RNA
targeting the insulin receptor (InR), insulin-like growth factor type 1
receptor (IGF-1R), IGF-2R, or nonspecific sequences (Scr). On P20,
rats were subjected to 10 incremental speed trials (from 2 to 10
rpm) of rotarod testing of motor function. Each trial was limited to
30 seconds duration. Data from (A) Trials 1-3 (2-4.5 rpm), (B) Trials 4-
6 (5-7.5 rpm), and (C) Trials 7-10 (8-10 rpm) were culled and
analyzed using the Mann-Whitney test. Panels display box plots
with means (bar), 95% confidence limits (box) and range (whiskers).
Significant P-values are indicated within the panels.
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Page 4 of 14Figure 2 Intracerebroventricular si-InR, si-IGF-1R, or si-IGF-2R impairs cerebellar development. Cerebella of rats treated by
intracerebroventricular (ICV) injection of si-RNA targeting (A,E,I) nonspecific sequences (Scr), (B,F,J) InR, (C,G,K) IGF-1R, or (D,H,L) IGF-2R, were
harvested on (A-H) P9 or (I-L) P20, sectioned in the mid-sagittal plane, fixed in Histochoice, and embedded in paraffin. Histological sections were
stained with Hematoxylin and Eosin. Photographs were taken at magnifications of (A-D) 100×, (E-H) 200×, or (I-L) 40×. (B-D) Note relative
simplification of the folia and variability in the thickness of the cortex, (D, H) reduced compactness and cellularity within the internal granule cell
layer, and (B-D, F-H) impaired development of white matter (wm) with (B,F,D,H) increased gliosis or (C,G) markedly reduced parenchymal volume
and appearance of cavitation one week after the ICV injections of si-Inr, si-IGF-1R, or si-IGF-2R relative to si-Scr controls (A,E). (I-L) In P20 rats, the
structural differences in cerebellar architecture caused by the si-RNA treatments were more subtle and mainly manifested by slightly more
irregular and shallow folia in (J) si-InR and (L) si-IGF-2R treated relative to (I) si-Scr controls. Abbreviations: igl = internal granule cell layer; egl =
external granule cell layer; pcl = Purkinje cell layer; wm = white matter; ml = molecular layer.
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InR, si-IGF-1R, or si-IGF-2R had increased levels HNE
immunoreactivity localized in the granule cell and Pur-
kinje cell layers, as well as in white matter glia. ICV
injection of si-IGF-2R increased HNE immunoreactivity
to a greater extent than the other si-RNA treatments.
The si-Scr treated control cerebella had abundant AAH
immunoreactivity distributed in Purkinje and granule
cells, as well as in neuropil fibrils. In contrast, ICV
transfection with si-RNA targeting InR, IGF-1R, or IGF-
2R was associated with lower levels of cerebellar AAH
immunoreactivity relative to control. However, si-InR
treatment resulted in increased AAH immunoreactivity
in reactive, hypertrophic astrocytes distributed among
granule cells.
ICV injection of si-InR, si-IGF-1R, or si-IGF-2R inhibits
cerebellar insulin, IGF-1, IGF-2 polypeptide and receptor
gene expression
ICV injection of si-InR significantly reduced the mean
mRNA levels of insulin, insulin receptor, and IGF-1R
relative to control. In addition, si-InR treated cerebella
had significantly lower mean levels of IGF-1, IGF-2,
insulin receptor, and IGF-1R relative to si-IGF-1R trea-
ted rats, and lower levels of IGF-2 compared with si-
IGF-2R treated rats (Figure 3). Rats treated by ICV
injection of si-IGF-1R had significantly higher cerebellar
levels of IGF-2 expression relative to control, higher
levels of insulin, IGF-1, IGF-2, insulin receptor, and
IGF-1R relative to si-InR treated rats, and higher levels
of IGF-2R relative to si-IGF-2R treated rats. ICV injec-
tion of si-IGF-2R significantly reduced IGF-1R and IGF-
2R expression relative to control.
si-InR, si-IGF-1R, and si-IGF-2R alter neurotrophin and
neurotrophin receptor expression in brain
We used qRT-PCR analysis (Figure 4) and ELISAs
(Figure 5) to measure expression of nerve growth factor,
brain derived neurotrophic factor (BDNF), p75 and neu-
ronal tyrosine (NRTK) kinase receptors in cerebellar tis-
sue (Figure 4). The qRT-PCR studies demonstrated
significantly lower mean levels of NGF in si-InR treated
relative to si-IGF-1R and si-IGF-2R treated rats. Other-
wise, the mRNA levels of BDNF, p75 and NRTK were
similar among the groups. ELISA studies (Figure 5)
revealed significant reductions in NT3 and BDNF neu-
rotrophin immunoreactivity in si-InR and/or si-IGF-1R
treated, but not si-IGF-2R treated cerebella relative to
control. The mean levels of NGF were similar in the
control and si-InR treated groups, but significantly ele-
vated relative to control in si-IGF-1R and si-IGF-2R
treated rats. The levels of NT3 immunoreactivity were
similar in control and si-IGF-2R treated rats, but signifi-
cantly reduced relative to control or si-IGF-2R in both
si-InR and si-IGF-1R treated rats. The mean levels of
BDNF immunoreactivity were similar in control, si-InR,
and si-IGF-1R treated rats, but significantly reduced in
the si-IGF-1R treated relative to control rats. In con-
trast, no significant inter-group differences were
observed with respect to NT4 expression.
Inhibition of insulin or IGF receptors alters tau, pTau,
ChAT, and GAPDH expression
Brain insulin/IGF resistance is associated with accumu-
lation of tau and phospho-tau, inhibition of cholinergic
function, and impairments in energy metabolism
[22,24,41,54,55]. ELISAs were used to measure tau,
phospho-tau (pTau), ChAT, AChE, b-Actin, and
GAPDH immunoreactivity (Figure 6). Both si-InR and
si-IGF-1R significantly increased tau immunoreactivity,
while si-InR significantly increased pTau, and si-IGF-1R
significantly increased b-Actin. ICV delivery of si-InR,
si-IGF-1R, and si-IGF-2R significantly reduced ChAT
immunoreactivity relative to control, but did not signifi-
cantly alter the mean levels of AChE immunoreactivity.
Finally, si-InR, but not si-IGF-1R or si-IGF-2R ICV
treatment reduced GAPDH expression in brain.
Discussion
Humans and experimental animals afflicted with FASD
have sustained impairments in cognitive and motor
functions. With regard to motor functions, the cerebel-
l u mi sam a j o rt a r g e to fa l c o h o l ’sn e u r o t o x i ca n d
teratogenic effects during development. Phenotypic
manifestations of FASD in the cerebellum include hypo-
plasia, hypofoliation, and disordered patterns of neuro-
nal migration [15-21,56,57]. These effects of prenatal
ethanol exposure are associated with impairments in
neuronal growth, survival, motility, adhesiveness, energy
metabolism, mitochondrial function, plasticity, and neu-
rotransmitter function, and increased oxidative stress
and DNA damage [22,25-27,42,54,58-67].
Ethanol mediates its adverse effects on CNS neurons
through inhibition of insulin and insulin-like growth fac-
tor (IGF) signaling [34,68,69]. Ethanol impairs binding
to the insulin/IGF receptors, preventing activation of
receptor tyrosine kinases that transmit signals down-
stream through IRS molecules [22-28]. In addition, etha-
nol inhibits other kinases, and it activates phosphatases
at various levels within the insulin/IGF signaling cas-
cades [27,70]. The net result is to reduce the levels and
duration of positive signaling. While these effects of
ethanol support our hypothesis that several fundamental
CNS abnormalities in FASD are attributable to impair-
ments in insulin and IGF signaling, they do not exclude
a role for neurotoxic injury caused by ethanol or its
metabolites. In this regard, it is noteworthy that oxida-
tive stress activates pro-inflammatory cytokines, which
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dysfunction, cell death, and insulin resistance
[24,25,31,32], while at the same time, insulin resistance
promotes oxidative stress. The present study attempts
clarify the contribution of reduced insulin and IGF sig-
naling as a mediator of impaired cerebellar development
and function as occur in FASD.
We used ICV injections to transfect immature brains
with si-RNA duplex molecules targeting InR, IGF1R,
IGF-2R, or nonspecific sequences (si-Scr). GFP expres-
sing plasmid DNA was co-transfected in order to confirm
success of the nucleic acid delivery. GFP expression,
detected by qRT-PCR analysis, peaked within 2-3 days of
gene delivery, and persisted throughout the period of
Figure 3 Inhibition of insulin and IGF signaling mechanisms in cerebella following ICV si-RNA delivery. Long Evans rat pups were
administered ICV injections of si-Scr, si-InR, si-IGF-1R, or si-IGF-2R on P2. Cerebella harvested on P24 were used to measure (A) insulin, (B) IGF-1,
(C) IGF-2, (D) insulin R, (E) IGF-1R, and (F) IGF-2R expression by qRT-PCR analysis with results normalized to 18S rRNA. Box plots depict means,
95% confidence intervals, and range for each group. Inter-group statistical comparisons were made using the Kruskal-Wallis one-way ANOVA and
the Dunn’s multiple comparisons post hoc test. Significant P-values are indicated within the panels.
de la Monte et al. Molecular Brain 2011, 4:13
http://www.molecularbrain.com/content/4/1/13
Page 7 of 14study. Previously, we used the same approach to generate
a model of neurodegeneration, and demonstrated sus-
tained transgene expression throughout the brain and in
all cell types [39]. However, multiple attempts to generate
similar models in adult brains proved unsuccessful. One
limitation of this model is the inability to truly examine
dose-effects since the method of gene suppression was
transient and based on delivery of si-RNA molecules. On
the other hand, an advantage of this approach is that the
RNA duplexes do not persist in the brain, and therefore,
any long-term effects could be attributed to transient tar-
geted disruption of gene expression during a critical per-
iod of development. Although we did not include data
from un-operated controls in this manuscript, the
rotarod performance and brain structure in si-Scr trans-
fected rats were comparable to previous findings in un-
operated controls.
Rotarod tests performed nearly 2 weeks after the ICV
injections revealed significant impairments in motor
function in the si-InR, si-IGF-1R, and si-IGF-2R relative
to si-Scr controls. Correspondingly, all 3 experimental
groups had conspicuous abnormalities in cerebellar
structure with hypotrophy, granule cell layer thinning
with hypoplasia, and hypofoliation. In addition, the
white matter cores were excessively thickened in si-InR
and si-IGF-1R treated rats, and markedly attenuated in
si-IGF-2R treated rats. Overall structural abnormalities
in the cerebellum were most pronounced in si-IGF-2R-
treated rats, suggesting that signaling through the IGF-
2R is critical for early postnatal cerebellar development.
The finding that Purkinje cells were relatively spared
corresponds with their earlier in utero development
[43,53,71]. Granule cells and white matter fibers develop
in the postnatal period when the si-RNA treatments
were administered.
Quantitative RT-PCR analysis showed that si-InR
broadly inhibited expression of insulin and IGF-2 poly-
peptides, and insulin, IGF-1, and IGF-2 receptors in
brain. ELISA studies confirmed that the si-InR treat-
ments inhibited expression of InR, IGF-1R, and IGF-2R.
The si-IGF-2R treatments had similar but more restric-
tive inhibitory effects on insulin/IGF polypeptide and
Figure 4 Effects of ICV administration of si-RNA targeting insulin or IGF receptors on neurotrophin and neurotrophin receptor
expression. Long Evans rat pups were administered ICV injections of si-Scr, si-InR, si-IGF-1R, or si-IGF-2R on P2. Cerebella harvested on P24 were
used to measure (A) NGF, (B) BDNF, (C) p75, and (D) NTRK expression by qRT-PCR analysis with results normalized to 18S rRNA. Box plots depict
means, 95% confidence intervals, and range for each group. Inter-group statistical comparisons were made using the Kruskal-Wallis one-way
ANOVA and the Dunn’s multiple comparisons post hoc test. Significant P-values are indicated within the panels.
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InR is co-expressed with IGF-1R or IGF-2R and/or that
insulin and IGF-2 polypeptides are expressed in InR-
and/or IGF-2R-positive cells. This overlap of signaling
mechanisms suggests that these related receptors serve
distinct functions during development, and the co-
expression of trophic factors suggests the existence of
either paracrine or autocrine stimulation networks. On
the other hand, impaired signaling through InR, as
occurs with ethanol exposure [22,72], reduces neuronal
survival, energy metabolism, neurotransmitter function,
particularly cholinergic, and mitochondrial function.
The attendant increased apoptosis of InR-positive cells
would likely reduce the population of IGF-1R- and IGF-
2R-bearing cells, and thereby decrease responsiveness to
insulin, IGF-1 and IGF-2, since InR and IGF-1R or IGF-
2R are likely co-expressed in developing cerebellar cells.
Reduced responsiveness to trophic factors would mimic
effects of insulin/IGF resistance. In addition, since insulin
and IGFs are expressed in InR, IGF-1R, and/or IGF-2R-
bearing cells, trophic factor resistance and attendant cell
loss would also lead to trophic factor deficiency. These
points are relevant to FASD because ethanol exposure
during development causes both insulin/IGF resistance
and deficiency in cerebella and cerebellar granule neurons
[22,27]. Moreover, the findings herein suggest that several
characteristic structural and functional cerebellar abnorm-
alities associated with FASD could be mediated by inhibi-
tion of signaling through the insulin and IGF receptors.
Corresponding with observations in other models of brain
insulin and IGF resistance, it may be possible to pre-
vent or reduce the severity of ethanol-induced neuro-
developmental abnormalities with insulin sensitizer
therapeutic agents such as peroxisome-proliferator
Figure 5 Effects of ICV injection of si-RNA targeting insulin or IGF receptors on neurotrophin immunoreactivity. Long Evans rat pups
were administered ICV injections of si-Scr, si-InR, si-IGF-1R, or si-IGF-2R on P2. Cerebella harvested on P24 were used to measure (A) NGF, (B)
BDNF, (C) NT3, and (D) NT4 immunoreactivity by ELISA, with results normalized to protein content within the wells. Immunoreactivity was
detected with horseradish peroxidase conjugated secondary antibody and the Amplex Red fluorophore. Fluorescence was measured in a
Spectramax M5 microplate reader (Ex 530 nm/Em 590 nm). Box plots depict means, 95% confidence intervals, and range for each group. Inter-
group statistical comparisons were made using the Kruskal-Wallis one-way ANOVA and the Dunn’s multiple comparisons test. Significant P-values
are indicated within the panels.
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Page 9 of 14Figure 6 Effects of ICV injection of si-RNA targeting insulin or IGF receptors on indices of neuronal structure and function. Long Evans
rat pups were administered ICV injections of si-Scr, si-InR, si-IGF-1R, or si-IGF-2R on P2. Cerebella harvested on P24 were used to measure (A)
Tau, (B) phospho-Tau; pTau), (C) choline acetyltransferase; ChAT (D) acetylcholinesterase; AChE, (E) b-Actin, and (F) GAPDH immunoreactivity by
ELISA with results normalized to protein content within the wells. Immunoreactivity was detected with horseradish peroxidase conjugated
secondary antibody and the Amplex Red fluorophore. Fluorescence was measured in a Spectramax M5 microplate reader (Ex 530 nm/Em 590
nm). Box plots depict means, 95% confidence intervals, and range for each group. Inter-group statistical comparisons were made using the
Kruskal-Wallis one-way ANOVA and the Dunn’s multiple comparisons test. Significant P-values are indicated within the panels.
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studies suggest that this approach would be effective
for restoring cerebellar function impaired by early
postnatal ethanol exposure [41].
Consequences of impaired insulin and IGF signaling
include inhibition of target gene expression and post-
translational modification of certain proteins. Insulin
and IGF regulate expression of GAPDH [74], ChAT
[75], and AAH [76]. Correspondingly, the studies herein
demonstrated that siRNA targeting of InR, IGF-1R, or
IGF-2R inhibited expression of all 3 proteins. In con-
trast, phospho-Tau, tau and b-actin levels were
increased. si-InR, si-IGF-1R, and si-IGF-2R inhibition of
GAPDH, which has an important role in energy meta-
bolism, could account for the associated increased cere-
bellar levels of HNE. HNE, a marker of oxidative stress
and lipid peroxidation, is also increased in brains
afflicted with FASD and in neuronal cells exposed to
ethanol in vitro [54]. ChAT, a major neurotransmitter
that mediates motor function, is stimulated by insulin or
IGFs, and correspondingly, ChAT expression was signifi-
cantly reduced in brains transfected with si-InR, si-IGF-
1R, or si-IGF-2R. This effect could account for the sig-
nificant impairments in Rotarod performance observed
in all 3 experimental groups. In contrast to ChAT, neu-
rotrophin and neurotrophin receptor expression were
relatively spared by the si-RNA treatments, with the
exceptions of NT3, which was inhibited by si-InR and
si-IGF-1R, and BDNF, which was suppressed by si-IGF-
1R. Both BDNF and NT3 are inhibited by ethanol [61],
and their expression and function are intimately tied to
insulin and IGF signal transduction cascades [77,78].
ICV delivery of si-InR, si-IGF-1R, or si-IGF-2R
reduced AAH immunoreactivity in cerebellar granule
cells as demonstrated by immunohistochemical staining.
AAH is another downstream target of insulin and IGF
stimulation [45,76] and a mediator of cell migration
[48,79]. AAH promotes cell motility by interacting with,
and hydroxylating Notch and its ligand, Jagged [80].
Notch signaling activates the transcription factors, HES
and HEY [81,82], which modulate expression of target
genes [83]. In FASD, impaired neuronal migration and
cerebellar foliation correlate with insulin/IGF resistance
and reduced AAH expression [44]. Since the si-RNA
treatments mimicked these effects of FASD, it is likely
that ethanol’s inhibition of insulin/IGF signaling is suffi-
cient to cause these teratogenic cerebellar abnormalities.
The increased cerebellar levels of phospho-tau in si-InR
treated rats is explainable on the basis of relative insulin
resistance since impaired insulin signaling leads to
increased activation of kinases, including GSK-3b,t h a t
promote tau phosphorylation [1]. High levels of phos-
pho-tau can be neurotoxic and frequently are associated
with neuronal injury, neurodegeneration, or oxidative
stress [50,69,84-87]. On the other hand, increased levels
of tau and b-actin immunoreactivity in si-InR and si-
IGF-1R treated rats, respectively suggest that impaired
insulin and IGF-1 signaling may result in accumulation
of cytoskeletal proteins. Although the consequences of
these effects are unknown, they could promote oxidative
stress and thereby contribute to the observed structural
and functional abnormalities in the brain.
The relevance of these findings to FASD is that, both
the ICV si-InR/IGF-R and developmental (prenatal or
early postnatal) exposures to ethanol cause cerebellar
hypoplasia with loss of cortical granule cells [22,27], dis-
ordered cell migration in the cerebellum [22,27], and
impaired performance on rotarod testing [41]. In addi-
tion, reduced expression of InR/IGF-R is associated with
reduced expression of insulin and IGF polypeptide genes,
GAPDH, ChAT, and AAH [22,27,44], and increased oxi-
dative stress [22,54] in cerebella of both the si-InR/IGF-R
and prenatal ethanol exposure models. Although we have
not yet published the effects of ethanol on tau expression
and phosphorylation in the brain, a recent study by Saito,
et al showed that early postnatal exposure to ethanol
leads to increased phosphorylation, cleavage, and degra-
dation of tau due to increased GSK-3b and caspase-3
activation in the developing brain [88]. Of note is that
similar mechanisms of AAH inhibition and degradation
were also demonstrated in our model of FASD [45].
Therefore, the increased tau phosphorylation observed in
cerebella of si-InR treated rats is also a feature of FASD.
In contrast to our finding of increased b-actin immunor-
eactivity in cerebella of si-InR and si-IGF-1R treated rats,
previous studies have demonstrated no significant effects
of ethanol on b-actin expression [45], and instead showed
that ethanol impairs cytoskeletal organization and adhe-
sion mechanisms [89]. Altogether, the adverse effects of
early postnatal ICV si-InR/IGF-R treatment on cerebellar
development and function are similar to but less severe
compared with FASD. The differences could be
accounted for in part by the fact that both insulin and
IGF receptors are impaired by ethanol, and that ethanol
as well as acetaldehyde exert pronounced toxic and meta-
bolic effects on immature neuronal cells [90].
Conclusions
The principal finding in this work were that molecular
inhibition of the insulin or IGF receptors in the develop-
ing brain is sufficient to produce many of the effects
associated with FASD in the cerebellum, including
structural abnormalities, impaired motor function,
altered expression of neurotrophins, neurotropin recep-
tors, and genes and proteins that are regulated by insu-
lin/IGF signaling, and increased oxidative stress. The
more pronounced adverse effects of ethanol relative to
ICV si-InR, si-IGF-1R, or si-IGF-2R could be attributed
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Page 11 of 14to broad-spectrum inhibition of these receptors and cor-
responding trophic factors, together with more pro-
nounced oxidative injury mediated by the toxic effects
of both ethanol and its chief metabolite, acetaldehyde.
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Additional file 1: Primer pairs used for qRT-PCR assays. The table
includes primer pair sequences, primer binding positions on the mRNA,
and the amplicon (PCR product) sizes.
Additional file 2: Effects of si-RNA treatments on oxidative stress
and AAH immunoreactivity. Figure depicting immunohistochemical
staining for 4-hydroxy-2-nonenal and aspartyl-(asparaginyl)-b-hydroxylase
(AAH) in cerebella of P16 rats that, on P2, were administered ICV
injections of (A,E) si-Scr, (B,F) si-InR, (C,G) si-IGF-1R, or (D,H) si-IGF-2R.
Paraffin-embedded histological sections of cerebella from P16 rats that
were administered ICV injections of (A,E) si-Scr, (B,F) si-InR, (C,G) si-IGF-1R,
or (D,H) si-IGF-2R on P2 were immunostained to detect (A-D) HNE as an
index of oxidative stress and lipid peroxidation, or (E-H) AAH, a gene
regulated by insulin/IGF stimulation and a mediator of neuronal
migration during development. Immunoreactivity was detected with
HRP-conjugated polymer-linked secondary antibody and DAB as the
chromogen (brown). Insets show higher magnification images of the
granule cell/Purkinje cell layers. Note minimal HNE immunoreactivity in
the si-Scr and si-IGF-1R treated brains, and increased labeling of both
granule (small round nuclei) and Purkinje (pyramid or star-shaped) cells
in the si-InR and si-IGF-2R treated brains. In contrast, AAH
immunoreactivity was robust in all cortical layers of si-Scr, si-InR, and si-
IGF-1R treated brains, and reduced in the granule cell layers of si-IGF-2R
treated brains. In addition, in the si-InR treated brains, Purkinje cells
exhibited intense AAH immunoreactivity (F). Original magnifications,
100×; insets, 400×.
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